1. Introduction {#sec1-molecules-23-01559}
===============

Pyrimidines scaffold have played a significant role in the area of medicinal chemistry \[[@B1-molecules-23-01559]\]. Pyrimidines are important moieties because of their potential biological activities such as antitumor, antiviral, and antibacterial agents \[[@B2-molecules-23-01559],[@B3-molecules-23-01559]\]. Dihydropyridines are the most potent calcium channel modulators available for the treatment of various cardiovascular diseases \[[@B4-molecules-23-01559]\]. Dihydropyrimidines, also known as Biginelli's compounds, display various pharmacological activities \[[@B5-molecules-23-01559]\]. Dihydropyrimidinone compounds were first synthesized by Pietro Biginelli. The process comprised of reacting numerous aldehydes with urea and a beta-keto ester to give a tetrahydropyrimidinone. Substituted dihydropyrimidinone compounds show interesting biological properties. Some of the analogs of dihydropyrimidine compounds are antitumor agents \[[@B6-molecules-23-01559]\]. Dihydropyrimidinones have emerged as calcium channel blockers and antihypertensive agents \[[@B7-molecules-23-01559]\]. These compounds exhibit a broad range of pharmacological activities, such as antibacterial, antitumor, antiviral, and anti-inflammatory \[[@B8-molecules-23-01559]\].

Piperazine moiety contains two nitrogen atoms at two opposite positions of a six-membered heterocyclic ring. Polar nitrogen atoms increase the favorable interactions of piperazine with macromolecules. It has the ability to cross the blood brain barrier (BBB) due to its lipophilic nature, and is useful in various diseases, such as Alzheimer's disease, psychosis, and depression. Many potent marketed drugs like fluphenazine, cinnarizine, flunarizine, lomerizine, ciprofloxacin, indinavir, etc., have a piperazine moiety ([Figure 1](#molecules-23-01559-f001){ref-type="fig"}). Piperazine derivatives have shown significant pharmacological activities, such as anti-tuberculosis, anti-inflammatory, antiviral, as Central Nervous System (CNS) agents, anticancer, as cardioprotective agents, and antidiabetic \[[@B9-molecules-23-01559],[@B10-molecules-23-01559],[@B11-molecules-23-01559],[@B12-molecules-23-01559],[@B13-molecules-23-01559],[@B14-molecules-23-01559],[@B15-molecules-23-01559],[@B16-molecules-23-01559],[@B17-molecules-23-01559],[@B18-molecules-23-01559],[@B19-molecules-23-01559],[@B20-molecules-23-01559],[@B21-molecules-23-01559],[@B22-molecules-23-01559],[@B23-molecules-23-01559],[@B24-molecules-23-01559],[@B25-molecules-23-01559],[@B26-molecules-23-01559],[@B27-molecules-23-01559],[@B28-molecules-23-01559]\].

Morpholine is an organic moiety containing nitrogen and oxygen in a heterocyclic six-membered ring, and is considered as an important building block in the field of medicinal chemistry. The linezolid antibiotic having a morpholine moiety is commercially available as antimicrobial agent. Timolol, moclobemide, emorfazone (anti-inflammatory drug and analgesic), phenadoxone (heptalgin, opioid analgesic), antidepressants reboxetine and gefitinib, fenpropimorph (fungicide) and antibacterial drugs finafloxacin and levofloxacin contain a morpholine moiety ([Figure 2](#molecules-23-01559-f002){ref-type="fig"}). Morpholine derivatives are very much essential in the drug discovery process. Morpholine scaffolds are important, due to their variety of pharmacological activities \[[@B29-molecules-23-01559],[@B30-molecules-23-01559],[@B31-molecules-23-01559],[@B32-molecules-23-01559],[@B33-molecules-23-01559],[@B34-molecules-23-01559],[@B35-molecules-23-01559]\].

The literature review suggested that molecules possessing these important scaffolds (piperazine/morpholine and dihydropyrimidinone) may have significant therapeutic activity. In the present disclosure, a series of novel piperazine/morpholine dihydropyrimidinone hybrids were prepared and analyzed by spectral data.

2. Results and Discussion {#sec2-molecules-23-01559}
=========================

As shown in ([Scheme 1](#molecules-23-01559-sch001){ref-type="scheme"}), enaminones, 4-methyl-1-\[4-(piperazin/morpholin-1-yl) phenyl\] pent-2-en-1-one (**IIa**--**b**) were synthesized by refluxing 1-\[4-(piperazin/morpholin-1-yl) phenyl\] ethan-1-one (**Ia**--**b**) with dimethylformamide dimethylacetal (DMF--DMA), without solvent for 10 h. To prepare the final dihydropyrimidinone derivatives, a mixture of substituted benzaldehyde (0.01 mol) **III**, enaminones (**IIa/IIb**) (0.01 mol), urea (0.01 mol) **IV**, and glacial acetic acid (10 mL) was heated on a heating mantle under refluxing condition for 3 h. The precipitates of compounds (**1**--**20**) were collected by vacuum filtration. The product was washed several times with water, and recrystallized from glacial acetic acid and ethanol mixture. ^1^H NMR spectrum of (**IIa**) displayed two singlets at δH 2.89, 3.12 ppm due to the *N*,*N*-dimethyl protons and two doublets at δH 5.80--5.82 and 7.63--7.65 ppm (d, *J* = 14 Hz) due to the ethylenic protons, in addition to the two doublets at the region δH 7.0 ppm (2H, d, aromatic) and δH 7.82 ppm (2H, d, aromatic). The protons of piperazine moiety appears at δH 3.40 (4H, singlet) and 3.52 (4H, singlet). ^1^H NMR spectrum of (**IIb**) displayed two singlets at δH 2.90, 3.12 ppm due to the *N*,*N*-dimethyl protons and two doublets at δH 5.80--5.82 and 7.63--7.65 ppm (d, *J* = 14 Hz) due to the ethylenic protons, in addition to the two doublets at the region δH 6.94 ppm (2H, d, aromatic) and δH 7.82 ppm (2H, d, aromatic). The protons of morpholine moiety appears at δH 3.21 (4H, singlet) and 3.74 (4H, singlet). The three-dimensional structure of enaminone (**IIb**) was confirmed by single crystal X-ray. The coupling constant (*J* = 14 Hz) for the ethylenic protons indicated that the enaminones existed in the *E*-configuration. Single crystal X-ray crystallography also confirmed the *E*-configuration of the enaminone \[[@B36-molecules-23-01559]\].

Compounds (**1**--**20**) presented the D~2~O exchangeable broad singlet at δH 6.71--8.52 ppm and δH 9.00--9.42 ppm corresponding to the two NH protons. The eight protons (4×CH~2~) of piperazine moiety were observed as singlet of four protons at δH 2.00--2.09, and another singlet of four protons at δH 3.20--3.41 ppm. The eight protons of morpholine moiety were observed as triplets at δH 3.20--3.22 ppm with coupling constant (*J* = 4.7 Hz) for four protons and another triplet at δH 3.72--3.82 with coupling constant (*J* = 4.6 Hz) for four protons. The H-4 and =CH protons of dihydropyrimidinone moiety were observed at δH 5.32--6.08 and 7.79--8.24 ppm, respectively \[[@B37-molecules-23-01559],[@B38-molecules-23-01559],[@B39-molecules-23-01559]\]. ^13^C NMR spectra confirmed the presence of all carbon atoms of compounds (**1**--**20**).

Mass spectral data confirmed the molecular weight of compounds. All the compounds presented molecular ion peak respective to their molecular weights. The experimental part contains the detailed spectral results of ^1^H NMR, ^13^C NMR spectra, and mass spectra. The information regarding the crystallographic data and refinement of the compound (**IIb**), C~15~H~20~N~2~O~2~ are summarized in [Table 1](#molecules-23-01559-t001){ref-type="table"}. The selected bond angles and bond lengths are listed in [Table 2](#molecules-23-01559-t002){ref-type="table"}. Two independent molecules were found in the asymmetric unit as shown in [Figure 3](#molecules-23-01559-f003){ref-type="fig"}. All the bond lengths and angles were in normal ranges as reported \[[@B40-molecules-23-01559]\]. The molecules were linked via two intermolecular hydrogen bonds in the crystal packing ([Figure 4](#molecules-23-01559-f004){ref-type="fig"}, [Table 3](#molecules-23-01559-t003){ref-type="table"}).

The mechanism involves the acid-catalyzed formation of iminium ion intermediate from the substituted benzaldehydes and urea. Reaction of iminium ion by enaminone of piperzine/morpholine produces ureidenone, which cyclizes to form hexahydropyrimidine. Elimination of N(CH~3~)~2~ group from hexahydropyrimidine in presence of glacial acetic acid produces final dihydropyrimidinone derivatives containing piperazine/morpholine moiety ([Scheme 2](#molecules-23-01559-sch002){ref-type="scheme"}).

3. Material and Methods {#sec3-molecules-23-01559}
=======================

3.1. Chemistry {#sec3dot1-molecules-23-01559}
--------------

All the solvents were purchased from Merck (Kenilworth, NJ, USA). To check the purity of compounds, thin layer chromatography (TLC), was performed on silica gel 60 F~254~ coated plates (Merck). For performing FTIR, Perkin Elmer (Waltham, MA, USA) FT-IR spectrophotometer was used. Melting points were measured by Gallenkamp melting point apparatus. ^1^H and ^13^C NMR were recorded in Bruker (Billerica, MA, USA) NMR 500/700 MHz and 125/176 MHz spectrophotometer. The samples were run in DMSO-*d*~6~ with tetramethyl silane (TMS) as an internal standard. Molecular weights of compounds were determined in mass spectroscopy. The elemental analysis of compounds was performed by CHN Elementar (Analysensysteme GmbH, Langenselbold, Germany). The compound (**IIb**) was obtained as single crystal by reported method. Data were collected on a Bruker APEX-II D8 Venture area diffractometer. SHELXT was used to solve structure \[[@B41-molecules-23-01559],[@B42-molecules-23-01559]\]. CCDC 1532829 contains the supplementary crystallographic data for the compound (**IIb**). These data can be obtained free of charge via <http://www.ccdc.cam.ac.uk/conts/retrieving.html> (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; Fax: +44 1223 336033; E-mail: <deposit@ccdc.cam.ac.uk>).

3.2. Synthesis of 3-(dimethylamino)-1-(4-(piperazin-1-yl) phenyl)prop-2-en-1-one *(**IIa**)* {#sec3dot2-molecules-23-01559}
--------------------------------------------------------------------------------------------

A mixture of 1-\[4-(piperazin-1-yl) phenyl\]ethan-1-one (**I**) (0.02 mol) and dimethylformamide dimethylacetal (DMF--DMA) (**II**) (0.023 mol) was refluxed for 10 h without solvent, then, the reaction mixture was left to cool slowly at room temperature. Diethyl ether was added to reaction mixture. The precipitate was obtained and filtration was performed under vacuum. The product was washed with cold diethyl ether. The product so obtained was recrystallized from absolute ethanol. Yield: 92%; m.p.: 105--107 °C; IR (KBr): νmax/cm^−1^: 1658 (C=O), 1541 (C=C), 1115 (C--O); ^1^H NMR (700 MHz, DMSO-*d*~6~) δ ppm: 8.10 (1H, s, NH), 7.82 (2H, d, *J* = 14 Hz, Ar--H), 7.63--7.65 (1H, d, *J* = 14 Hz, =CH), 7.0 (2H, d, *J* = 7 Hz, Ar--H) 5.80--5.82 (1H, d, *J* = 14 Hz, =CH), 3.52 (4H, s, piperazine), 3.40 (4H, s, piperazine), 3.12 (3H, s, N--CH~3~), 2.89 (3H, s, N--CH~3~); ^13^C NMR (176.0 MHz, DMSO-*d*~6~): δ = 26.2, 44.6, 46.8, 48.0, 91.0, 114.1, 127.5, 129.2, 130.5, 153.7, 154.0, 161.4, 185.1, 196.1; MS: *m*/*z* = 259.16 \[M\]^+^; Analysis: for C~15~H~21~N~3~O, calcd. C 69.47, H 8.16, N 16.20%; found C 69.20, H 8.14, N 16.14%.

3.3. Synthesis of 3-(dimethylamino)-1-(4-morpholinophenyl)prop-2-en-1-one *(**IIb**)* {#sec3dot3-molecules-23-01559}
-------------------------------------------------------------------------------------

Yield: 90%; m.p.: 210--212 °C; IR (KBr): νmax/cm^−1^: 1640 (C=O), 1540 (C=C), 1111 (C--O); ^1^H NMR (700 MHz, DMSO-*d*~6~) δ ppm: 7.82 (2H, d, *J* = 7 Hz, Ar--H), 7.63--7.65 (1H, d, *J* = 14 Hz, =CH), 6.94 (2H, d, *J* = 7 Hz, Ar--H) 5.80--5.82 (1H, d, *J* = 14 Hz, =CH), 3.74 (4H, s, morpholine), 3.21 (4H, s, morpholine), 3.12 (3H, s, N--CH~3~), 2.90 (3H, s, N--CH~3~); ^13^C NMR (176.0 MHz, DMSO-*d*~6~): *δ* = 26.6, 47.2, 47.8, 66.42, 91.1, 113.7, 130.5, 130.7, 153.7, 185.1, 196.1; MS: *m*/*z* = 260.1 \[M\]^+^; Analysis: for C~15~H~20~N~2~O~2~, calcd. C 69.20, H 7.74, N 10.76%; found C 69.22, H 7.72, N 10.70%.

3.4. General Synthesis of 4-(substituted phenyl)-5-\[4-(piperazin/morpholin-1-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one *(**1**--**20**)* {#sec3dot4-molecules-23-01559}
-------------------------------------------------------------------------------------------------------------------------------------------

A mixture of enaminones, (2*E*)-4-methyl-1-\[4-(piperazin/morpholin-1-yl) phenyl\] pent-2-en-1-one (0.01 mol), differently substituted benzaldehydes (0.01 mol), urea (0.01 mol), and glacial acetic acid (10 mL) were refluxed for 3 h on a heating mantle. The reaction mixture was precipitated by pouring into the cold water. The products were obtained by vacuum filtration. The final products were recrystallized from glacial acetic acid and ethanol.

*4-Phenyl-5-\[4-(piperazin-1-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**1**): Yield: 75%; m.p.: 150--152 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.41 (1H, s, NH, D~2~O exch), 8.50 (1H, s, NH, D~2~O exch), 8.0 (1H, s, =CH), 6.90--7.80 (9H, m, Ar--H), 6.0 (1H, s, H-4), 3.40 (2H, s, CH~2~ *piperazine*), 3.31 (2H, s, CH~2~ *piperazine*), 2.06 (2H, s, CH~2~ *piperazine*), 2.0 (2H, s, CH~2~ *piperazine*), 1.80 (1H, s, NH, D~2~O exch); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): *δ* = 44.6 (CH~2~), 47.0 (CH~2~), 48.0 (CH), 50.10 (CH~2~), 65.5 (CH~2~), 111.5, 113.0, 114.0, 114.2, 124.4, 130.5, 134.1, 138.7, 148.0, 149.0, 151.0, 161.1, 168.0, 190.40 (C=O), 207.0 (C=O) MS: *m*/*z* = 362.42 \[M\]^+^; Analysis: for C~21~H~22~N~4~O~2~, calcd. C 69.59, H 6.12, N 15.46%; found C 69.32, H 6.10, N 15.40%.

*4-(2-Nitrophenyl)-5-\[4-(piperazin-1-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**2**)*:* Yield: 70%; m.p.: 170--172 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.40 (1H, s, NH, D~2~O exch), 8.52 (1H, s, NH, D~2~O exch), 8.04 (1H, s, =CH), 6.89--7.88 (8H, m, Ar--H), 6.07 (1H, s, H-4), 3.41 (2H, s, CH~2~ *piperazine*), 3.32 (2H, s, CH~2~ *piperazine*), 2.06 (2H, s, CH~2~ *piperazine*), 2.0 (2H, s, CH~2~ *piperazine*), 1.79 (1H, s, NH, D~2~O exch); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): *δ* = 44.7 (CH~2~), 47.2 (CH~2~), 48.4 (CH), 50.11 (CH~2~), 65.4 (CH~2~), 111.7, 113.6, 114.1, 114.5, 124.4, 130.5, 134.1, 138.7, 148.3, 149.1, 151.2, 161.5, 168.9, 190.40 (C=O), 207.0 (C=O); MS: *m*/*z* = 407.40 \[M\]^+^; Analysis: for C~21~H~21~N~5~O~4~, calcd. C 61.91, H 5.20, N 17.19%; found C 62.15, H 5.22, N 17.12%.

*4-(4-Nitrophenyl)-5-\[4-(piperazin-1-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**3**): Yield: 75%; m.p.: 175--177 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.41 (1H, s, NH, D~2~O exch), 8.28 (1H, s, =CH), 6.93--7.58 (8H, m, Ar--H), 7.93 (1H, s, NH, D~2~O exch), 5.55 (1H, s, H-4), 3.30 (2H, s, CH~2~ *piperazine*), 3.23 (2H, s, CH~2~ *piperazine*), 2.07 (2H, s, CH~2~ *piperazine*), 2.0 (2H, s, CH~2~ *piperazine*), 1.85 (1H, s, NH, D~2~O exch); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): *δ* = 44.7 (CH~2~), 45.5 (CH~2~), 47.5 (CH), 48.0 (CH~2~), 53.9 (CH~2~), 118.8, 114.1, 124.3, 128.3, 130.6, 147.2, 151.6, 153.1, 161.3, 168.8, 190.4 (C=O), 207.0 (C=O); MS: *m*/*z* = 407.42 \[M\]^+^; Analysis: for C~21~H~21~N~5~O~4~, calcd. C 61.91, H 5.20, N 17.19%; found C 62.10, H 5.23, N 17.13%.

*4-(3-Nitrophenyl)-5-\[4-(piperazin-1-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**4**): Yield: 75%; m.p.: 180--182 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.42 (1H, s, NH, D~2~O exch), 8.23 (1H, s, =CH), 6.93--7.65 (8H, m, Ar--H), 7.95 (1H, s, NH, D~2~O exch), 5.58 (1H, s, H-4), 3.31 (2H, s, CH~2~ *piperazine*), 3.23 (2H, s, CH~2~ *piperazine*), 2.07 (2H, s, CH~2~ *piperazine*), 2.01 (2H, s, CH~2~ *piperazine*), 1.87 (1H, s, NH, D~2~O exch); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): *δ* = 44.7 (CH~2~), 47.2 (CH~2~), 48.0 (CH), 53.8 (CH~2~), 65.4 (CH~2~), 111.8, 114.1, 121.6, 122.9, 128.3, 130.3, 131.3, 133.7, 146.7, 148.2, 151.6, 161.3, 168.8, 190.5 (C=O), 207.0 (C=O); MS: *m*/*z* = 407.42 \[M\]^+^; Analysis: for C~21~H~21~N~5~O~4~, calcd. C 61.91, H 5.20, N 17.19%; found C 60.67, H 5.22, N 17.10%.

*4-(4-Chlorophenyl)-5-\[4-(piperazin-1-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**5**): Yield: 75%; m.p.: 160--162 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.32 (1H, s, NH, D~2~O exch), 8.50 (1H, s, NH, D~2~O exch), 8.23 (1H, s, =CH), 6.95--8.11 (8H, m, Ar--H), 5.46 (1H, s, H-4), 3.31 (2H, s, CH~2~ *piperazine*), 3.23 (2H, s, CH~2~ *piperazine*), 2.09 (2H, s, CH~2~ *piperazine*), 2.04 (2H, s, CH~2~ *piperazine*), 1.90 (1H, s, NH, D~2~O exch); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): *δ* = 44.7 (CH~2~), 47.3 (CH~2~), 48.4 (CH), 53.6 (CH~2~), 65.4 (CH~2~), 112.5, 114.1, 115.6, 116.0, 128.5, 140.0, 143.6, 148.1, 151.8, 153.1, 156.7, 161.3, 168.7, 190.5 (C=O), 207.0 (C=O); MS: *m*/*z* = 396.87 \[M\]^+^; Analysis: for C~21~H~21~ClN~4~O~2~, calcd. C 63.55, H 5.33, N 14.12%; found C 63.31, H 5.34, N 14.17%.

*4-(2-Methoxyphenyl)-5-\[4-(piperazin-1-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**6**): Yield: 75%; m.p.: 120--122 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.22 (1H, s, NH, D~2~O exch), 8.51 (1H, s, NH, D~2~O exch), 8.13 (1H, s, =CH), 6.93--7.98 (8H, m, Ar--H), 5.77 (1H, s, H-4), 3.82 (3H, s, OCH~3~), 3.41 (2H, s, CH~2~ *piperazine*), 3.24 (2H, s, CH~2~ *piperazine*), 2.09 (2H, s, CH~2~ *piperazine*), 2.04 (2H, s, CH~2~ *piperazine*), 1.93 (1H, s, NH, D~2~O exch); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): *δ* = 44.6 (CH~2~), 46.7 (CH~2~), 49.6 (CH), 55.9 (CH~2~), 56.1 (CH~2~), 111.1, 114.2, 120.6, 130.5, 131.0, 137.3, 154.0, 157.3, 158.5, 161.4, 168.8, 172.6, 187.1, 190.5, 196.1 (C=O), 207.0 (C=O); MS: *m*/*z* = 392.45 \[M\]^+^; Analysis: for C~22~H~24~N~4~O~3~, calcd. C 67.33, H 6.16, N 14.28%; found C 67.58, H 6.14, N 14.23%.

*4-(4-Hydroxyphenyl)-5-\[4-(piperazin-1-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**7**): Yield: 75%; m.p.: 210--212 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.16 (1H, s, OH, D~2~O exch), 9.0 (1H, s, NH, D~2~O exch), 8.51 (1H, s, NH, D~2~O exch), 8.17 (1H, s, =CH), 6.71--8.08 (8H, m, Ar--H), 5.33 (1H, s, H-4), 3.35 (2H, s, CH~2~ *piperazine*), 3.20 (2H, s, CH~2~ *piperazine*), 2.07 (2H, s, CH~2~ *piperazine*), 2.01 (2H, s, CH~2~ *piperazine*), 1.82 (1H, s, NH, D~2~O exch); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): *δ* = 44.7 (CH~2~), 48.1 (CH~2~), 49.2 (CH), 53.5 (CH~2~), 65.4 (CH~2~), 115.4, 116.0, 128.0, 129.6, 130.3, 151.7, 152.0, 153.0, 155.8, 156.4, 157.1, 159.1, 161.3, 168.8, 190.7 (C=O), 207.0 (C=O); MS: *m*/*z* = 378.42 \[M\]^+^; Analysis: for C~21~H~22~N~4~O~3~, calcd. C 66.65, H 5.86, N 14.81%; found C 66.40, H 5.84, N 14.86%.

*4-(3-Hydroxyphenyl)-5-\[4-(piperazin-1-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**8**): Yield: 75%; m.p.: 158--160 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.8 (1H, s, OH, D~2~O exch), 9.10 (1H, s, NH, D~2~O exch), 8.04 (1H, s, =CH), 6.82--7.77 (8H, m, Ar--H), 6.71 (1H, s, NH, D~2~O exch), 5.32 (1H, s, H-4), 3.30 (2H, s, CH~2~ *piperazine*), 3.20 (2H, s, CH~2~ *piperazine*), 2.04 (2H, s, CH~2~ *piperazine*), 2.0 (2H, s, CH~2~ *piperazine*), 1.86 (1H, s, NH, D~2~O exch); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): *δ* = 44.6 (CH~2~), 46.7 (CH~2~), 48.0 (CH), 53.8 (CH~2~), 56.5 (CH~2~), 115.5, 117.3, 120.1, 122.9, 128.6, 130.5, 136.7, 139.5, 143.0, 146.1, 152.1, 153.1, 154.0, 157.8, 161.4, 168.8, 172.6, 187.0, 190.6, 196.6 (C=O), 207.0 (C=O); MS: *m*/*z* = 378.42 \[M\]^+^; Analysis: for C~21~H~22~N~4~O~3~, calcd. C 66.65, H 5.86, N 14.81%; found C 66.39, H 5.83, N 14.85%.

*4-(3-Methoxyphenyl)-5-\[4-(piperazin-1-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**9**): Yield: 70%; m.p.: 118--120 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.28 (1H, s, NH, D~2~O exch), 8.50 (1H, s, NH, D~2~O exch), 8.24 (1H, s, =CH), 6.88--8.11 (8H, m, Ar--H), 5.47 (1H, s, H-4), 3.73 (3H, s, OCH~3~), 3.33 (2H, s, CH~2~ *piperazine*), 3.20 (2H, s, CH~2~ *piperazine*), 2.09 (2H, s, CH~2~ *piperazine*), 2.04 (2H, s, CH~2~ *piperazine*), 1.92 (1H, s, NH, D~2~O exch); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): *δ* = 44.6 (CH~2~), 46.8 (CH~2~), 47.3 (CH), 55.4 (CH~2~), 65.4 (CH~2~), 112.7, 114.1, 118.9, 130.5, 136.8, 139.9, 142.8, 146.1, 151.7, 152.0, 153.1, 154.0, 159.7, 160.1, 161.4, 172.7, 187.0, 190.6, 196.1 (C=O), 207.0 (C=O); MS: *m*/*z* = 392.45 \[M\]^+^; Analysis: for C~22~H~24~N~4~O~3~, calcd. C 67.33, H 6.16, N 14.28%; found C 67.57, H 6.14, N 14.23%.

*4-(3-Ethoxyphenyl)-5-\[4-(piperazin-1-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**10**): Yield: 65%; m.p.: 88--90 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.21 (1H, s, NH, D~2~O exch), 8.52 (1H, s, NH, D~2~O exch), 8.20 (1H, s, =CH), 6.87--8.11 (8H, m, Ar--H), 5.40 (1H, s, H-4), 4.0 (2H, q, OCH~2~), 3.33 (2H, s, CH~2~ *piperazine*), 3.20 (2H, s, CH~2~ *piperazine*), 2.09 (2H, s, CH~2~ *piperazine*), 2.08 (2H, s, CH~2~ *piperazine*), 1.92 (1H, s, NH, D~2~O exch), 1.35 (3H, t, CH~3~); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): *δ* = 15.0 (CH~3~), 44.6 (OCH~2~), 46.8 (CH~2~), 47.3 (CH~2~), 48.0 (CH), 48.5 (CH~2~), 63.7 (CH~2~), 114.2, 115.1, 128.0, 130.5, 130.9, 131.0, 153.9, 158.2, 160.8, 161.4, 172.5, 186.9, 190.6, 191.7, 196.1 (C=O), 207.0 (C=O); MS: *m*/*z* = 406.43 \[M\]^+^; Analysis: for C~23~H~26~N~4~O~3~, calcd. C 67.96, H 6.45, N 13.78%; found C 67.70, H 4.46, N 13.73%.

*5-\[4-(Morpholin-4-yl)benzoyl\]-4-phenyl-3,4-dihydropyrimidin-2(1H)-one* (**11**): Yield: 70%; m.p.: 258--260 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.21 (1H, s, NH, D~2~O exch), 7.79 (1H, s, =CH), 7.09--7.45 (6H, m, Ar--H), 7.01 (1H, s, NH, D~2~O exch), 6.95 (3H, m, Ar--H), 5.44 (1H, s, H-4), 3.74 (4H, t, *J* = 4.6 Hz, 2×CH~2~ *morpholine*), 3.22 (4H, t, *J* = 4.8 Hz, 2×CH~2~ *morpholine*); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): δ = 47.6 (CH~2~), 47.7 (CH~2~), 54.0 (CH), 66.35 (CH~2~), 66.37 (CH~2~), 112.9, 113.81, 113.84, 126.8, 127.8, 128.5, 128.9, 130.4, 130.5, 139.8, 144.6, 151.9, 153.3, 153.5, 190.6 (C=O), 194.0 (C=O); MS: *m*/*z* = 363.42 \[M\]^+^; Analysis: for C~21~H~21~N~3~O~3~, calcd. C 69.41, H 5.82, N 11.56%; found C 69.58, H 5.80, N 11.59%.

*5-\[4-(Morpholin-4-yl)benzoyl\]-4-(2-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-one* (**12**): Yield: 75%; m.p.: 198--200 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.42 (1H, d, NH, D~2~O exch), 8.07 (1H, s, =CH), 7.06--7.91 (8H, m, Ar--H), 6.93 (1H, s, NH, D~2~O exch), 6.08 (1H, s, H-4), 3.73 (4H, t, *J* = 4.6 Hz, 2×CH~2~ *morpholine*), 3.21 (4H, t, *J* = 4.7 Hz, 2×CH~2~ *morpholine*); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): δ = 47.0 (CH~2~), 47.6 (CH~2~), 50.0 (CH), 66.2 (CH~2~), 66.3 (CH~2~), 111.7, 113.4, 124.4, 128.1, 129.2, 130.0, 132.6, 134.3, 138.7, 140.8, 148.3, 151.1, 153.5, 190.3 (C=O), 192.8 (C=O); MS: *m*/*z* = 408.43 \[M\]^+^; Analysis: for C~21~H~20~N~4~O~5~, calcd. C 61.76, H 4.94, N 13.72%; found C 61.90, H 4.92, N 13.77%.

*5-\[4-(Morpholin-4-yl)benzoyl\]-4-(4-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-one* (**13**): Yield: 70%; m.p.: 202--204 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.42 (1H, d, NH, D~2~O exch), 8.23 (1H, s, =CH), 7.43--7.92 (6H, m, Ar--H), 7.09 (1H, s, NH, D~2~O exch), 6.94 (2H, d, *J* = 8.9 Hz, Ar--H), 5.57 (1H, s, H-4), 3.72 (4H, t, *J* = 4.6 Hz, 2×CH~2~ *morpholine*), 3.21 (4H, t, *J* = 4.7 Hz, 2×CH~2~ *morpholine*); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): δ = 47.60 (CH~2~), 46.67 (CH~2~), 53.9 (CH), 66.2 (CH~2~), 66.3 (CH~2~), 111.8, 113.8, 124.3, 128.2, 128.3, 130.5, 134.0, 138.0, 140.7, 147.2, 151.7, 151.8, 153.6, 190.5 (C=O), 192.0 (C=O); MS: *m*/*z* = 408.42 \[M\]^+^; Analysis: for C~21~H~20~N~4~O~5~, calcd. C 61.76, H 4.94, N 13.72%; found C 61.90, H 4.92, N 13.76%.

*5-\[4-(Morpholin-4-yl)benzoyl\]-4-(3-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-one* (**14**): Yield: 70%; m.p.: 205--207 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.40 (1H, d, NH, D~2~O exch), 8.15 (1H, s, =CH), 7.45--7.95 (6H, m, Ar--H), 7.12 (1H, s, NH, D~2~O exch), 6.95 (2H, d, *J* = 8.9 Hz, Ar--H), 5.59 (1H, s, H-4), 3.72 (4H, t, *J* = 4.6 Hz, 2×CH~2~ *morpholine*), 3.22 (4H, t, *J* = 4.7 Hz, 2×CH~2~ *morpholine*); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): δ = 47.6 (2×CH~2~), 53.7 (CH), 66.3 (2×CH~2~), 111.8, 113.8, 121.6, 122.9, 128.2, 130.5, 130.7, 133.7, 140.8, 146.7, 148.2, 151.6, 153.6, 190.5 (C=O), 192.0 (C=O); MS: *m*/*z* = 408.41 \[M\]^+^; Analysis: for C~21~H~20~N~4~O~5~, calcd. C 61.76, H 4.94, N 13.72%; found C61.89, H 4.91, N 13.75%.

*4-(4-Chlorophenyl)-5-\[4-(morpholin-4-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**15**): Yield: 80%; m.p.: 288--290 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.25 (1H, d, NH, D~2~O exch), 7.81 (1H, s, =CH), 7.33--7.45 (6H, m, Ar--H), 7.02 (1H, s, NH, D~2~O exch), 6.95 (2H, d, *J* = 8.5 Hz, Ar--H), 5.43 (1H, s, H-4), 3.73 (4H, t, *J* = 4.6 Hz, 2×CH~2~ *morpholine*), 3.22 (4H, t, *J* = 4.7 Hz, 2×CH~2~ *morpholine*); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): δ = 47.6 (2×CH~2~), 53.6 (CH), 66.3 (2×CH~2~), 112.5, 113.8, 128.4, 128.8, 128.9, 130.5, 132.3, 140.1, 143.6, 151.8, 153.5, 190.6 (C=O), 192.0 (C=O); MS: *m*/*z* = 397.86 \[M\]^+^; Analysis: for C~21~H~20~ClN~3~O~3~, calcd. C 63.40, H 5.07, N 10.56%; found C 63.65, H 5.08, N 10.59%.

*4-(2-Methoxyphenyl)-5-\[4-(morpholin-4-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**16**): Yield: 80%; m.p.: 178--180 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.22 (1H, s, NH, D~2~O exch), 7.81 (1H, s, =CH), 7.20--7.50 (5H, m, Ar--H), 7.09 (1H, s, NH, D~2~O exch), 6.89--7.01 (3H, m, Ar--H), 5.75 (1H, s, H-4), 3.82 (4H, t, *J* = 4.7 Hz, 2×CH~2~ *morpholine*), 3.21 (4H, t, *J* = 4.7 Hz, 2×CH~2~ *morpholine*); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): δ = 47.6 (2×CH~2~), 49.6 (OCH~3~), 55.9 (CH), 66.2 (CH~2~), 66.3 (CH~2~), 111.5, 117.7, 113.8, 120.7, 127.9, 128.7, 129.3, 130.5, 131.3, 140.4, 152.2, 153.5, 157.3, 190.5 (C=O), 192.0 (C=O); MS: *m*/*z* = 393.41 \[M\]^+^; Analysis: for C~22~H~23~N~3~O~4~, calcd. C 67.16, H 5.89, N 10.68%; found C 66.89, H 5.87, N 10.64%.

*4-(4-Hydroxyphenyl)-5-\[4-(morpholin-4-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**17**): Yield: 60%; m.p.: 118--120 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.14 (1H, s, NH, D~2~O exch), 9.01 (1H, s, OH), 8.08 (1H, s, =CH), 7.43--7.77 (4H, m, Ar--H), 7.07 (1H, s, NH, D~2~O exch), 6.70--7.05 (4H, m, Ar--H), 5.35 (1H, s, H-4), 3.74 (4H, t, *J* = 4.6 Hz, 2×CH~2~ *morpholine*), 3.21 (4H, t, *J* = 4.6 Hz, 2×CH~2~ *morpholine*); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): δ = 47.0 (CH~2~), 47.6 (CH~2~), 53.5 (CH), 66.2 (CH~2~), 66.4 (CH~2~), 113.4, 113.8, 115.5, 128.0, 128.6, 130.5, 132.6, 135.2, 139.3, 152.0, 153.5, 154.5, 154.7, 190.7 (C=O), 191.8 (C=O); MS: *m*/*z* = 379.41 \[M\]^+^; Analysis: for C~21~H~21~N~3~O~4~, calcd. C 66.48, H 5.58, N 11.08%; found C 66.72, H 5.60, N 11.04%.

*4-(3-Hydroxyphenyl)-5-\[4-(morpholin-4-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**18**): Yield: 60%; m.p.: 120--122 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.19 (1H, s, NH, D~2~O exch), 9.01 (1H, s, OH), 8.08 (1H, s, =CH), 7.43--7.77 (4H, m, Ar--H), 7.06 (1H, s, NH, D~2~O exch), 6.63--7.01 (4H, m, Ar--H), 5.37 (1H, s, H-4), 3.72 (4H, t, *J* = 4.6 Hz, 2×CH~2~ *morpholine*), 3.20 (4H, t, *J* = 4.6 Hz, 2×CH~2~ *morpholine*); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): *δ* = 48.3 (CH~2~), 48.5 (CH~2~), 55.2 (CH), 66.7 (CH~2~), 67.6 (CH~2~), 114.6, 115.0, 131.2, 131.8, 138.9, 140.1, 140.8, 147.4, 153.4, 154.6, 154.8, 155.8, 159.2, 192.0 (C=O), 194.0 (C=O); MS: *m*/*z* = 379.42 \[M\]^+^; Analysis: for C~21~H~21~N~3~O~4~, calcd. C 66.48, H 5.58, N 11.08%; found C 66.63, H 5.59, N 11.12%.

*4-(3-Methoxyhenyl)-5-\[4-(morpholin-4-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**19**): Yield: 60%; m.p.: 170--172 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.23 (1H, d, NH, D~2~O exch), 8.09 (1H, s, =CH), 7.24--7.79 (4H, m, Ar--H), 6.87 (1H, s, NH, D~2~O exch), 6.91--7.04 (4H, m, Ar--H), 5.45 (1H, s, H-4), 3.83 (3H, s, OCH~3~), 3.73 (4H, t, *J* = 4.6 Hz, 2×CH~2~ *morpholine*), 3.22 (4H, t, *J* = 4.6 Hz, 2×CH~2~ *morpholine*); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): δ = 47.0 (CH~2~), 47.6 (CH~2~), 53.9 (OCH~3~), 55.4 (CH), 66.2 (CH~2~), 66.3 (CH~2~), 112.77, 112.79, 112.93, 113.8, 118.9, 128.5, 130.1, 130.5, 139.8, 146.1, 152.0, 153.5, 159.7, 190.7 (C=O), 192.0 (C=O); MS: *m*/*z* = 393.40 \[M\]^+^; Analysis: for C~22~H~23~N~3~O~4~, calcd. C 67.16, H 5.89, N 10.68%; found C 66.87, H 5.91, N 10.66%.

*4-(4-Ethoxyphenyl)-5-\[4-(morpholin-4-yl)benzoyl\]-3,4-dihydropyrimidin-2(1H)-one* (**20**): Yield: 60%; m.p.: 200--202 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): *δ* = 9.16 (1H, s, NH, D~2~O exch), 8.08 (1H, s, =CH), 6.86--7.77 (8H, m, Ar--H), 6.78 (1H, s, NH, D~2~O exch), 5.38 (1H, s, H-4), 3.97 (2H, q, *J* = 6.9 Hz, OCH~2~), 3.73 (4H, t, *J* = 4.6 Hz, 2×CH~2~ *morpholine*), 3.21 (4H, t, *J* = 4.6 Hz, 2×CH~2~ *morpholine*), 1.27 (3H, t, *J* = 6.9 Hz, CH~3~); ^13^C NMR (125.76 MHz, DMSO-*d*~6~): δ = 18.0 (CH~3~), 47.0 (CH~2~), 47.7 (CH~2~), 53.4 (OCH~2~), 63.2 (CH~2~), 66.3 (CH~2~), 113.2, 114.2, 125.8, 128.0, 129.5, 132.7, 136.7, 138.8, 139.5, 151.9, 153.3, 154.6, 157.1, 158.2, 190.7 (C=O), 192.8 (C=O); MS: *m*/*z* = 407.42 \[M\]^+^; Analysis: for C~23~H~25~N~3~O~4~, calcd. C 67.80, H 6.18, N 10.31%; found C 66.88, H 6.20, N 10.35%.

4. Conclusions {#sec4-molecules-23-01559}
==============

In conclusion, novel dihydropyrimidinone derivatives (**1**--**20**) containing piperazine and morpholine moieties were synthesized efficiently in good yield with a simple method consisting of three components in a single pot. The starting material, enaminones, 4-methyl-1-\[4-(piperazin/morpholin-1-yl) phenyl\] pent-2-en-1-one (**IIa**--**b**) were synthesized by reacting 4-methyl-1-\[4-(piperazin/morpholin-1-yl) phenyl\] pent-2-en-1-one (**Ia**--**b**) with dimethylformamide dimethylacetal (DMF--DMA) without solvent. The *E* -configuration of the enaminone was confirmed by the single crystal X-ray crystallography.

**Sample Availability:** Samples of the compounds (**1**--**20**) with 99% purity are available from authors.
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![Marketed drugs containing piperazine moiety.](molecules-23-01559-g001){#molecules-23-01559-f001}

![Marketed drugs containing morpholine moiety.](molecules-23-01559-g002){#molecules-23-01559-f002}

![Reaction scheme for the synthesis of dihydropyrimidinone derivatives (**1**--**20**).](molecules-23-01559-sch001){#molecules-23-01559-sch001}

![ORTEP diagram of the enaminone (**IIb**) containing morpholine moiety. Displacement ellipsoids are plotted at the 40% probability level for non-H atoms.](molecules-23-01559-g003){#molecules-23-01559-f003}

![Molecular packing of enaminone (**IIb**) viewed hydrogen bonds which are drawn as dashed lines along *a* axis.](molecules-23-01559-g004){#molecules-23-01559-f004}

![Mechanism of the reaction for the synthesis of dihydropyrimidinone derivatives (**1**--**20**).](molecules-23-01559-sch002){#molecules-23-01559-sch002}

molecules-23-01559-t001_Table 1

###### 

Experimental details.

  Crystal Data                                                           
  ---------------------------------------------------------------------- ------------------------------------------------------------------------
  Chemical formula                                                       C~15~H~20~N~2~O~2~
  Mr                                                                     260.33
  Crystal system, space group                                            Triclinic, *P*-1
  Temperature (K)                                                        293
  *a*, *b*, *c* (Å)                                                      9.5268 (7), 10.2914 (8), 15.3140 (11)
  *α β* γ (°)                                                            104.458 (3), 97.224 (3), 97.984 (3)
  V (Å3)                                                                 1419.51 (18)
  *Z*                                                                    4
  Radiation type                                                         Mo *K*α
  µ (mm^−1^)                                                             0.08
  Crystal size (mm)                                                      0.61 × 0.31 × 0.28
  **Data collection**                                                    
  Diffractometer                                                         Bruker APEX-II D8 venture diffractometer
  Absorption correction                                                  Multi-scan SADABS Bruker 2014
  Tmin, Tmax                                                             0.952, 0.977
  No. of measured, independent and observed \[I \> 2σ(I)\] reflections   27345, 5007, 2799
  R~int~                                                                 0.102
  **Refinement**                                                         
  R\[*F*^2^ \> 2σ(*F*^2^)\], wR(*F*^2^), S                               0.075, 0.239, 1.04
  No. of reflections                                                     5007
  No. of parameters                                                      348
  No. of restraints                                                      0
  H-atom treatment                                                       H atoms treated by a mixture of independent and constrained refinement
  Δρ~max~, Δρ~min~ (e Å^−3^)                                             0.34, −0.32

molecules-23-01559-t002_Table 2

###### 

Selected geometric parameters (Å).

  ------------------- ----------- ------------------- -----------
  O1A---C8A           1.393 (5)   N2A---C13A          1.326 (4)
  O1A---C9A           1.399 (5)   N2A---C14A          1.429 (5)
  O2A---C11A          1.230 (4)   N2A---C15A          1.443 (4)
  O1B---C9B           1.327 (6)   N1B---C1B           1.402 (4)
  O1B---C8B           1.369 (5)   N1B---C7B           1.406 (5)
  O2B---C11B          1.233 (5)   N1B---C10B          1.427 (5)
  N1A---C10A          1.460 (4)   N2B---C13B          1.332 (5)
  N1A---C1A           1.403 (4)   N2B---C14B          1.440 (4)
  N1A---C7A           1.447 (5)   N2B---C15B          1.453 (6)
  C8A---O1A---C9A     110.1 (3)   N1A---C7A---C8A     111.8 (3)
  C8B---O1B---C9B     117.7 (3)   O1A---C8A---C7A     113.1 (3)
  C1A---N1A---C10A    117.1 (2)   O1A---C9A---C10A    112.6 (3)
  C7A---N1A---C10A    111.9 (3)   N1A---C10A---C9A    111.4 (3)
  C1A---N1A---C7A     117.5 (2)   O2A---C11A---C4A    118.5 (3)
  C13A---N2A---C15A   121.8 (3)   O2A---C11A---C12A   123.1 (3)
  C14A---N2A---C15A   116.7 (3)   N2A---C13A---C12A   127.7 (3)
  C13A---N2A---C14A   121.5 (3)   N1B---C1B---C2B     121.2 (3)
  C1B---N1B---C7B     118.9 (3)   N1B---C1B---C6B     122.0 (3)
  C1B---N1B---C10B    119.3 (3)   N1B---C7B---C8B     115.9 (3)
  C7B---N1B---C10B    117.4 (3)   O1B---C8B---C7B     116.9 (4)
  C13B---N2B---C14B   122.6 (3)   O1B---C9B---C10B    119.2 (4)
  C13B---N2B---C15B   121.2 (3)   N1B---C10B---C9B    115.8 (3)
  C14B---N2B---C15B   115.9 (3)   O2B---C11B---C4B    119.0 (3)
  N1A---C1A---C2A     122.5 (3)   O2B---C11B---C12B   121.6 (3)
  N1A---C1A---C6A     120.4 (3)   N2B---C13B---C12B   128.1 (4)
  ------------------- ----------- ------------------- -----------

molecules-23-01559-t003_Table 3

###### 

Hydrogen-bond geometry (Å).

  D---H···A                                 D---H   H···A    D···A       D---H···A
  ----------------------------------------- ------- -------- ----------- -----------
  C5B---H5BA···O2B^i^                       0.930   2.5100   3.391 (4)   158.00
  C13A---H13A···O2B^i^                      0.930   2.5900   3.451 (4)   154.00
  C13B---H13B···O2A^i^                      0.930   2.5800   3.418 (4)   151.00
  C15A---H15A···O2B^i^                      0.960   2.5100   3.375 (5)   149.00
  Symmetry code: (i) --x + 1, −y + 1, −z.                                
